Lenacapavir: could new HIV drug help end the pandemic?
- Forfatter
- Afsnit
- 894
- Udgivet
- 23. jul. 2024
- Forlag
- 0 Anmeldelser
- 0
- Afsnit
- 894 of 1142
- Længde
- 20M
- Sprog
- Engelsk
- Format
- Kategori
- Fakta
“That will be a miracle on its own because when I started taking ARVs I began with 20 tablets.”
In June, the US drug company Gilead announced that a trial of its HIV drug Lenacapavir had got a 100% success rate.
The drug - a twice-yearly injection – can be used to protect people from catching the virus, but also to treat those who have it.
But the question of pricing remains – with people in poor countries unable to afford the current price tag of $40,000 per person per year. One analysis has suggested it could be mass produced as a generic drug for about $40 per person per year.
In this episode of Africa Daily podcast Peter Musembi speaks to Dr Moupali Das who oversees the development of HIV prevention drugs at Gilead – and also gets reaction with two people living with HIV.
Other podcasts you might like ...
- M’usa, con l’apostrofo. Le donne di PicassoLetizia Bravi
- FC PopCornFilm Companion
- Do I Like It?The Quint
- The Big StoryThe Quint
- DiskoteksbrandenAntonio de la Cruz
- Dragon gateEdith Söderström
- En amerikansk epidemiPatrick Stanelius
- En värld i brand: Andra världskriget och sanningenAnton Vretander
- FamiljenFrida Anund
- Hagen-fallet: Spårlöst försvunnenAntonio de la Cruz
- M’usa, con l’apostrofo. Le donne di PicassoLetizia Bravi
- FC PopCornFilm Companion
- Do I Like It?The Quint
- The Big StoryThe Quint
- DiskoteksbrandenAntonio de la Cruz
- Dragon gateEdith Söderström
- En amerikansk epidemiPatrick Stanelius
- En värld i brand: Andra världskriget och sanningenAnton Vretander
- FamiljenFrida Anund
- Hagen-fallet: Spårlöst försvunnenAntonio de la Cruz
